Prospective evaluation of PI-RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion-guided biopsy.

IF 2.1 4区医学 Japanese Journal of Radiology Pub Date : 2025-03-01 Epub Date: 2024-10-16 DOI:10.1007/s11604-024-01675-4

Naohiro Yamaya, Koichiro Kimura, Ryota Ichikawa, Masaaki Kawanishi, Yusuke Kawasaki, Subaru Higuchi, Kenichi Fukui, Junichi Tsuchiya, Masaki Kobayashi, Soichiro Yoshida, Yasuhisa Fujii, Ukihide Tateishi

{"title":"Prospective evaluation of PI-RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion-guided biopsy.","authors":"Naohiro Yamaya, Koichiro Kimura, Ryota Ichikawa, Masaaki Kawanishi, Yusuke Kawasaki, Subaru Higuchi, Kenichi Fukui, Junichi Tsuchiya, Masaki Kobayashi, Soichiro Yoshida, Yasuhisa Fujii, Ukihide Tateishi","doi":"10.1007/s11604-024-01675-4","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the cancer detection rates for each category of Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) using multiparametric magnetic resonance imaging (mpMRI) and biparametric MRI (bpMRI) based on MRI/ultrasound (US)-fusion biopsy.Materials and methods: This prospective study included participants who underwent mpMRI or bpMRI with a PI-RADSv2.1 interpretation and subsequently received MRI/US-fusion biopsy between August 2022 and December 2023. The lesion-based detection rates of clinically significant prostate cancer (csPCa) in each PI-RADSv2.1 category and the correlation between PI-RADSv2.1 categories and International Society of Urological Pathology (ISUP) grade groups were analyzed. The diagnostic performance of PI-RADSv2.1 in predicting csPCa was evaluated, and diagnostic performance of mpMRI and bpMRI was compared using cut-offs, with PI-RADSv2.1 categories ≥ 3 or ≥ 4 defined as positive.Results: A total of 247 lesions from 216 participants were included in this study. A total of 157 patients underwent mpMRI and the remaining 59 underwent bpMRI. The csPCa detection rates for each PI-RADSv2.1 category of mpMRI and bpMRI were as follows: category 1, 0% (0/11); 2, 13% (3/23); 3, 16% (5/31); 4, 60% (43/72); 5, 65% (26/40), in mpMRI; category 1, 0% (0/4); 2, 33% (1/3); 3, 25% (3/12); 4, 61% (19/31); 5, 75% (15/20) in bpMRI. PI-RADSv2.1 categories were significantly positively associated with csPCa detection rates in both mpMRI and bpMRI (p < 0.0001 and p = 0.00048, respectively). PI-RADSv2.1 categories correlated with ISUP grade groups for mpMRI and bpMRI (p < 0.0001 for both). There were no significant differences in the detection rates between mpMRI and bpMRI for PI-RADS v2.1 positive and negative lesions.Conclusion: PI-RADSv2.1 using mpMRI and bpMRI could stratify the risk of csPCa, and the csPCa detection rate of bpMRI was compatible with that of mpMRI using cut-offs of PI-RADSv2.1 categories ≥ 3 or ≥ 4.","PeriodicalId":14691,"journal":{"name":"Japanese Journal of Radiology","volume":" ","pages":"472-482"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868320/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11604-024-01675-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the cancer detection rates for each category of Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) using multiparametric magnetic resonance imaging (mpMRI) and biparametric MRI (bpMRI) based on MRI/ultrasound (US)-fusion biopsy.

Materials and methods: This prospective study included participants who underwent mpMRI or bpMRI with a PI-RADSv2.1 interpretation and subsequently received MRI/US-fusion biopsy between August 2022 and December 2023. The lesion-based detection rates of clinically significant prostate cancer (csPCa) in each PI-RADSv2.1 category and the correlation between PI-RADSv2.1 categories and International Society of Urological Pathology (ISUP) grade groups were analyzed. The diagnostic performance of PI-RADSv2.1 in predicting csPCa was evaluated, and diagnostic performance of mpMRI and bpMRI was compared using cut-offs, with PI-RADSv2.1 categories ≥ 3 or ≥ 4 defined as positive.

Results: A total of 247 lesions from 216 participants were included in this study. A total of 157 patients underwent mpMRI and the remaining 59 underwent bpMRI. The csPCa detection rates for each PI-RADSv2.1 category of mpMRI and bpMRI were as follows: category 1, 0% (0/11); 2, 13% (3/23); 3, 16% (5/31); 4, 60% (43/72); 5, 65% (26/40), in mpMRI; category 1, 0% (0/4); 2, 33% (1/3); 3, 25% (3/12); 4, 61% (19/31); 5, 75% (15/20) in bpMRI. PI-RADSv2.1 categories were significantly positively associated with csPCa detection rates in both mpMRI and bpMRI (p < 0.0001 and p = 0.00048, respectively). PI-RADSv2.1 categories correlated with ISUP grade groups for mpMRI and bpMRI (p < 0.0001 for both). There were no significant differences in the detection rates between mpMRI and bpMRI for PI-RADS v2.1 positive and negative lesions.

Conclusion: PI-RADSv2.1 using mpMRI and bpMRI could stratify the risk of csPCa, and the csPCa detection rate of bpMRI was compatible with that of mpMRI using cut-offs of PI-RADSv2.1 categories ≥ 3 or ≥ 4.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用多参数和双参数磁共振成像对 PI-RADSv2.1 进行前瞻性评估，以便根据磁共振成像/超声波融合引导的活组织检查检测出具有临床意义的前列腺癌。

目的：评估使用多参数磁共振成像（mpMRI）和基于磁共振成像/超声（US）-融合活检的双参数磁共振成像（bpMRI）的前列腺成像-报告和数据系统 2.1 版（PI-RADSv2.1）的各类癌症检出率：这项前瞻性研究纳入了在2022年8月至2023年12月期间接受了具有PI-RADSv2.1解释的mpMRI或bpMRI检查并随后接受了MRI/US融合活检的参与者。研究分析了每个 PI-RADSv2.1 类别中具有临床意义的前列腺癌（csPCa）的病灶检出率，以及 PI-RADSv2.1 类别与国际泌尿病理学会（ISUP）分级组之间的相关性。评估了PI-RADSv2.1在预测csPCa方面的诊断性能，并使用临界值比较了mpMRI和bpMRI的诊断性能，将PI-RADSv2.1类别≥3或≥4定义为阳性：本研究共纳入了 216 名参与者的 247 个病灶。共有 157 名患者接受了 mpMRI 检查，其余 59 名患者接受了 bpMRI 检查。每个 PI-RADSv2.1 类别的 mpMRI 和 bpMRI 的 csPCa 检测率分别为 0.5%和 0.5%。1 类别的 csPCa 检测率如下：mpMRI 中，类别 1，0%（0/11）；2，13%（3/23）；3，16%（5/31）；4，60%（43/72）；5，65%（26/40）；bpMRI 中，类别 1，0%（0/4）；2，33%（1/3）；3，25%（3/12）；4，61%（19/31）；5，75%（15/20）。在 mpMRI 和 bpMRI 中，PI-RADSv2.1 类别与 csPCa 检出率呈显著正相关（p 结论：PI-RADSv2.1 类别与 csPCa 检出率呈显著正相关：使用 mpMRI 和 bpMRI 的 PI-RADSv2.1 可以对 csPCa 的风险进行分层，使用 PI-RADSv2.1 类别≥ 3 或≥ 4 的截断值，bpMRI 的 csPCa 检测率与 mpMRI 的 csPCa 检测率一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Japanese Journal of Radiology Medicine-Radiology, Nuclear Medicine and Imaging

自引率

4.80%

发文量

133

期刊介绍： Japanese Journal of Radiology is a peer-reviewed journal, officially published by the Japan Radiological Society. The main purpose of the journal is to provide a forum for the publication of papers documenting recent advances and new developments in the field of radiology in medicine and biology. The scope of Japanese Journal of Radiology encompasses but is not restricted to diagnostic radiology, interventional radiology, radiation oncology, nuclear medicine, radiation physics, and radiation biology. Additionally, the journal covers technical and industrial innovations. The journal welcomes original articles, technical notes, review articles, pictorial essays and letters to the editor. The journal also provides announcements from the boards and the committees of the society. Membership in the Japan Radiological Society is not a prerequisite for submission. Contributions are welcomed from all parts of the world.